Drug Trial News

RSS

The business of clinical trials is booming. Private equity has taken notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.

2 Dec 2022

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

A Phase 1 clinical trial provides promising results for a broadly neutralizing antibody (bnAb) HIV vaccine, according to a new study.

1 Dec 2022

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

1 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.

30 Nov 2022

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke's Hospital and the University of Cambridge has found.

28 Nov 2022

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon.

23 Nov 2022

Morphine does not reduce worst breathlessness, study finds

Sometimes healthcare professionals treat patients with opioids such as morphine to relieve symptoms, but there has been a lack of evidence as to whether this helps with severe chronic breathlessness.

23 Nov 2022

Hungary sees 116% growth in non-invasive prenatal testing

...

From BGI Genomics 21 Nov 2022

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Telethon Kids Institute is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.

14 Nov 2022

Oral deucravacitinib shows promise in patients with active lupus

Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus.

14 Nov 2022

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab - a human monoclonal antibody that targets the type I IFN receptor - in patients with lupus.

14 Nov 2022

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

Experts at Duke Health were among a multi-national team involved in treating a fetus for infantile-onset Pompe disease using an enzyme replacement therapy - a first in the world.

9 Nov 2022

Psilocybin could be a promising therapeutic strategy for people with treatment-resistant depression

Researchers at Trinity College Dublin have participated in the largest and most rigorous clinical trial to date of psilocybin (a psychoactive ingredient in magic mushrooms), pointing to the possibility that COMP360 psilocybin with psychological support could be a beneficial therapeutic strategy for people with treatment-resistant depression (TRD).

7 Nov 2022

Novel drug lowers triglycerides, does not reduce cardiovascular events

Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice.

6 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

An estimated 6.2 million Americans ages 65 and older are living with Alzheimer's disease. The national Alzheimer's Association predicts that number to grow to 13.8 million by 2060, barring the development of medical breakthroughs that would prevent, slow or cure the debilitating disease.

2 Nov 2022

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.

1 Nov 2022

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

31 Oct 2022

Previous
1
...
46
47
48
49
50
51
52
...
1162
Next

Drug Trial News

The business of clinical trials is booming. Private equity has taken notice.

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Morphine does not reduce worst breathlessness, study finds

Hungary sees 116% growth in non-invasive prenatal testing

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Oral deucravacitinib shows promise in patients with active lupus

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

Psilocybin could be a promising therapeutic strategy for people with treatment-resistant depression

Novel drug lowers triglycerides, does not reduce cardiovascular events

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News